K. Rowland Yeo

发表

Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability

G. Tucker, A. Rostami-Hodjegan, E. Howgate, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Modeling and predicting drug pharmacokinetics in patients with renal impairment

M. Jamei, A. Rostami-Hodjegan, K. Rowland Yeo, 2011, Expert review of clinical pharmacology.

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan

L. V. von Moltke, K. Rowland Yeo, Lei Sun, 2020, CPT: pharmacometrics & systems pharmacology.

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling

K. Rowland Yeo, L. Almond, H. Jones, 2020, Clinical pharmacology and therapeutics.

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations

B. Small, K. Rowland Yeo, T. Johnson, 2022, CPT: pharmacometrics & systems pharmacology.

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Kuan-Fu Chen, K. Rowland Yeo, S. Neuhoff, 2022, CPT: pharmacometrics & systems pharmacology.

The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism

G. Tucker, M. Ozdemir, A. Rostami-Hodjegan, 2016, Biopharmaceutics & drug disposition.

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study

K. Venkatakrishnan, K. Rowland Yeo, 2020, Clinical pharmacology and therapeutics.

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

K. Rowland Yeo, S. Neuhoff, I. Gardner, 2018, Clinical pharmacology and therapeutics.

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam.

Masoud Jamei, Amin Rostami-Hodjegan, Geoffrey T Tucker, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

M. Jamei, R. Walsky, G. Tucker, 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

D. Esseltine, K. Venkatakrishnan, J. Nemunaitis, 2017, Journal of clinical pharmacology.

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors

A. Rostami-Hodjegan, K. Rowland Yeo, H. Crewe, 2011, Biopharmaceutics & drug disposition.

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination

L. V. von Moltke, K. Rowland Yeo, Lei Sun, 2020, Clinical Pharmacokinetics.

Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2

K. Rowland Yeo, D. Plowchalk, 2012, European Journal of Clinical Pharmacology.

Another Step Toward Qualification of Pediatric Physiologically Based Pharmacokinetic Models to Facilitate Inclusivity and Diversity in Pediatric Clinical Studies

B. Small, K. Rowland Yeo, T. Johnson, 2022, Clinical pharmacology and therapeutics.

CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision

E. Sobie, V. Sinha, K. Rowland Yeo, 2021, CPT: pharmacometrics & systems pharmacology.

PBPK modeling of ivermectin—Considerations for the purpose of developing alternative routes to optimize its safety profile

K. Rowland Yeo, D. Wesche, 2023, CPT: pharmacometrics & systems pharmacology.

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet

L. V. von Moltke, K. Rowland Yeo, Z. Barter, 2021, CPT: pharmacometrics & systems pharmacology.

Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo

E. Howgate, K. Rowland Yeo, M. Turner, 2023, Drug Metabolism and Disposition.

Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants

K. Rowland Yeo, Xian Pan, 2023, Clinical pharmacology and therapeutics.

M. Jamei, G. Tucker, A. Rostami-Hodjegan, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2

K. Rowland Yeo, Karen Rowland Yeo, D. Plowchalk, 2012, European Journal of Clinical Pharmacology.